Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Neoadjuvant, Randomized, Multicenter Study of Imprime PGG Plus Pembrolizumab in Subjects With Stage III, Resectable Melanoma

NCT04995094 is registered in ClinicalTrials.gov with HiberCell, Inc. as lead sponsor.

NCT NCT04995094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04995094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Neoadjuvant, Randomized, Multicenter Study of Imprime PGG Plus Pembrolizumab in Subjects With Stage III, Resectable Melanoma
Lead sponsor
HiberCell, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
August 15, 2021
Completion date
May 18, 2023
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pathologic stage iii cutaneous melanoma ajcc v8